Literature DB >> 23823325

Magic bullets from llamas.

Daniel J Leahy1.   

Abstract

Monoclonal antibodies are effective therapies for many disorders, but their nature and use continues to evolve as technologies emerge to improve their drug-like qualities. In this issue of Structure, Schmitz and colleagues report on structural and biophysical characterizations of single-domain "nanobodies" from llamas that target the epidermal growth factor receptor by both old and new mechanisms.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23823325      PMCID: PMC3758895          DOI: 10.1016/j.str.2013.06.008

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  10 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

Review 2.  Introduction to heavy chain antibodies and derived Nanobodies.

Authors:  Cécile Vincke; Serge Muyldermans
Journal:  Methods Mol Biol       Date:  2012

3.  Replacing the complementarity-determining regions in a human antibody with those from a mouse.

Authors:  P T Jones; P H Dear; J Foote; M S Neuberger; G Winter
Journal:  Nature       Date:  1986 May 29-Jun 4       Impact factor: 49.962

4.  Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.

Authors:  Shiqing Li; Karl R Schmitz; Philip D Jeffrey; Jed J W Wiltzius; Paul Kussie; Kathryn M Ferguson
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

Review 5.  Treatment of HER2-positive breast cancer: current status and future perspectives.

Authors:  Carlos L Arteaga; Mark X Sliwkowski; C Kent Osborne; Edith A Perez; Fabio Puglisi; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2011-11-29       Impact factor: 66.675

6.  Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains.

Authors:  Karl R Schmitz; Atrish Bagchi; Rob C Roovers; Paul M P van Bergen en Henegouwen; Kathryn M Ferguson
Journal:  Structure       Date:  2013-06-20       Impact factor: 5.006

7.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

8.  Antibody-based therapy in colorectal cancer.

Authors:  Takuro Noguchi; Gerd Ritter; Hiroyoshi Nishikawa
Journal:  Immunotherapy       Date:  2013-05       Impact factor: 4.196

9.  Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.

Authors:  Judith Schmiedel; Andree Blaukat; Shiqing Li; Thorsten Knöchel; Kathryn M Ferguson
Journal:  Cancer Cell       Date:  2008-04       Impact factor: 31.743

Review 10.  An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.

Authors:  Antony W Burgess; Hyun-Soo Cho; Charles Eigenbrot; Kathryn M Ferguson; Thomas P J Garrett; Daniel J Leahy; Mark A Lemmon; Mark X Sliwkowski; Colin W Ward; Shigeyuki Yokoyama
Journal:  Mol Cell       Date:  2003-09       Impact factor: 17.970

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.